FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

研究用のみ。 完全な免責事項 →

ペプチドライブラリー

Kisspeptin-10

Metastin 45-54 / KP-10 / KISS1

Sexual Health

Kisspeptin-10 is a truncated, biologically active fragment of the kisspeptin family of peptides, derived from the KiSS-1 gene product. It is the most upstream regulator of the hypothalamic-pituitary-gonadal (HPG) axis, directly stimulating GnRH neurons to initiate the reproductive hormone cascade. It is an emerging research compound in reproductive endocrinology, with applications in fertility diagnostics, IVF protocols, and understanding puberty initiation.

作用機序

C-terminal decapeptide fragment of kisspeptin that activates GPR54 (KISS1R) receptors on GnRH neurons. Potently stimulates the hypothalamic-pituitary-gonadal (HPG) axis, triggering pulsatile GnRH release and downstream LH and FSH secretion.

研究プロトコル

研究目的のみで使用。医療アドバイスではありません。

Research protocols use 1-10mcg/kg via IV infusion or subcutaneous injection. Single-dose studies commonly use 1nmol/kg IV. Very short-acting; effects on LH occur within minutes.

研究ノート

Clinical Research Status

Kisspeptin-10 is in early-phase clinical research primarily at academic centers, with Imperial College London leading human studies for IVF and reproductive disorders. Clinical trials have demonstrated its ability to trigger LH pulses and stimulate oocyte maturation as a potential alternative to HCG triggers in IVF. It is not yet approved for any therapeutic indication but has orphan-like research status in reproductive medicine.

Key Published Findings

Human studies demonstrate that kisspeptin-10 infusion (at doses of 0.1-1.0 nmol/kg) potently stimulates LH and FSH secretion in healthy volunteers and patients with reproductive disorders. In IVF contexts, kisspeptin-triggered oocyte maturation has produced viable pregnancies with theoretically lower risk of ovarian hyperstimulation syndrome compared to HCG triggers. Research confirms kisspeptin neurons are the critical gatekeepers of puberty onset, integrating metabolic and circadian signals to initiate HPG axis activation.

Safety Profile

Kisspeptin-10 has demonstrated an excellent safety profile in human clinical studies, with no serious adverse events reported across multiple Phase 1/2 trials. Its short half-life (approximately 4-5 minutes for kisspeptin-10) means effects are rapidly reversible, reducing risk of prolonged overstimulation. Unlike HCG triggers in IVF, kisspeptin stimulation produces a more physiological gonadotropin surge that may reduce ovarian hyperstimulation syndrome risk.

Comparison to Related Compounds

Unlike gonadorelin which directly activates GnRH receptors on the pituitary, kisspeptin acts one step further upstream by stimulating GnRH neurons themselves, producing a more physiological hormonal cascade. Compared to HCG for IVF triggering, kisspeptin produces a shorter and more physiological LH surge. The kisspeptin-54 (full-length) form has a longer half-life than kisspeptin-10 but both activate the same GPR54 (KISS1R) receptor.

Community Observations

Kisspeptin-10 has attracted interest from reproductive endocrinology researchers as a potentially safer alternative for IVF trigger protocols, particularly in OHSS-prone patients. The peptide's position at the apex of the HPG axis makes it a uniquely informative diagnostic tool for distinguishing hypothalamic from pituitary causes of hypogonadism. Its extremely short half-life currently limits practical therapeutic applications outside of controlled clinical settings.

半減期

~28 minutes

再構成

Sterile saline or bacteriostatic water

保存

乾燥粉末

Store at -20C for long term.

再溶解

Refrigerate 2-8C. Use within 7 days.

米国法的状況

Research chemical (not FDA-approved)

また知られる名前

Metastin 45-54KP-10KISS1

よくある質問

Kisspeptin-10とは何ですか?

Kisspeptin-10 is a truncated, biologically active fragment of the kisspeptin family of peptides, derived from the KiSS-1 gene product. It is the most upstream regulator of the hypothalamic-pituitary-gonadal (HPG) axis, directly stimulating GnRH neurons to initiate the reproductive hormone cascade. It is an emerging research compound in reproductive endocrinology, with applications in fertility diagnostics, IVF protocols, and understanding puberty initiation.

Kisspeptin-10はどのように作用しますか?

C-terminal decapeptide fragment of kisspeptin that activates GPR54 (KISS1R) receptors on GnRH neurons. Potently stimulates the hypothalamic-pituitary-gonadal (HPG) axis, triggering pulsatile GnRH release and downstream LH and FSH secretion.

Kisspeptin-10の米国での規制状況は?

Research chemical (not FDA-approved)

Kisspeptin-10の半減期は?

~28 minutes

Kisspeptin-10の別名は?

Metastin 45-54, KP-10, KISS1

ペプチドコンタクトは、研究目的のみのための要約情報を提供しています。私たちはベンダーの文書をホスト、配布、または推奨していません。すべての分析証明書、GMP認定証明書、およびベンダーコミュニケーションは、購入者によって直接要求され、確認される必要があります。このプラットフォーム上の何らかの情報は法的、医学的、または専門的なアドバイスを構成していません。ユーザーは、適切な法律、州法、および連邦法に準拠するためにベンダー資格を検証し、購入前に遵守することに全責任を持つ必要があります。このプラットフォームを使用することで、完全な個人的責任を承認することになります。

完全な免責事項を読む